Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

R. B. Verheijen; E. L. Swart; J. H. Beijnen; J. H.M. Schellens; A. D.R. Huitema; N. Steeghs

doi:10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

R. B. Verheijen
, E. L. Swart
, J. H. Beijnen
, J. H.M. Schellens
, A. D.R. Huitema
, N. Steeghs

Research output: Contribution to journal › Comment/debate

Abstract

In the original publication of the article, the second author name has been misspelled.

Original language	English
Pages (from-to)	163
Number of pages	1
Journal	Cancer chemotherapy and pharmacology
Volume	86
Issue number	1
DOIs	https://doi.org/10.1007/s00280-020-04090-4
Publication status	Published - 1 Jul 2020
Externally published	Yes

Access to Document

10.1007/s00280-020-04090-4

Fingerprint

Dive into the research topics of 'Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)'. Together they form a unique fingerprint.

Cite this

Verheijen, R. B., Swart, E. L., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., & Steeghs, N. (2020). Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). Cancer chemotherapy and pharmacology, 86(1), 163. https://doi.org/10.1007/s00280-020-04090-4

Verheijen, R. B. ; Swart, E. L. ; Beijnen, J. H. et al. / Correction to : Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). In: Cancer chemotherapy and pharmacology. 2020 ; Vol. 86, No. 1. pp. 163.

@article{698308cfd8804d4f8868254c9234b229,

title = "Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)",

abstract = "In the original publication of the article, the second author name has been misspelled.",

author = "Verheijen, \{R. B.\} and Swart, \{E. L.\} and Beijnen, \{J. H.\} and Schellens, \{J. H.M.\} and Huitema, \{A. D.R.\} and N. Steeghs",

note = "Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2020",

month = jul,

day = "1",

doi = "10.1007/s00280-020-04090-4",

language = "English",

volume = "86",

pages = "163",

journal = "Cancer chemotherapy and pharmacology",

issn = "0344-5704",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Verheijen, RB, Swart, EL, Beijnen, JH, Schellens, JHM, Huitema, ADR & Steeghs, N 2020, 'Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)', Cancer chemotherapy and pharmacology, vol. 86, no. 1, pp. 163. https://doi.org/10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). / Verheijen, R. B.; Swart, E. L.; Beijnen, J. H. et al.
In: Cancer chemotherapy and pharmacology, Vol. 86, No. 1, 01.07.2020, p. 163.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

AU - Verheijen, R. B.

AU - Swart, E. L.

AU - Beijnen, J. H.

AU - Schellens, J. H.M.

AU - Huitema, A. D.R.

AU - Steeghs, N.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - In the original publication of the article, the second author name has been misspelled.

AB - In the original publication of the article, the second author name has been misspelled.

UR - https://www.scopus.com/pages/publications/85086340810

U2 - 10.1007/s00280-020-04090-4

DO - 10.1007/s00280-020-04090-4

M3 - Comment/debate

C2 - 32524189

AN - SCOPUS:85086340810

SN - 0344-5704

VL - 86

SP - 163

JO - Cancer chemotherapy and pharmacology

JF - Cancer chemotherapy and pharmacology

IS - 1

ER -

Verheijen RB, Swart EL, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). Cancer chemotherapy and pharmacology. 2020 Jul 1;86(1):163. doi: 10.1007/s00280-020-04090-4